Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities

Pasquale Esposito, Edoardo La Porta, Marta Calatroni, Maria Antonietta Grignano, Samantha Milanesi, Daniela Verzola, Yuri Battaglia, Marilena Gregorini, Carmelo Libetta, Giacomo Garibotto, Teresa Rampino

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. In this study we investigated the relevance of myostatin and Hepatocyte Growth Factor (HGF) in patients undergoing hemodialysis HD and the influence of different HD modalities on their levels. Methods. We performed a prospective crossover study in which HD patients were randomized to undergo 3-month treatment periods with bicarbonate hemodialysis (BHD) followed by online hemodiafiltration (HDF). Clinical data, laboratory parameters, and myostatin and HGF serum levels were collected and compared. Results. Ten patients and six controls (C) were evaluated. In any experimental condition myostatin and HGF levels were higher in HD than in C. At enrollment and after BHD there were not significant correlations, whereas at the end of the HDF treatment period myostatin and HGF were inversely correlated (r -0.65, p<0.05), myostatin serum levels inversely correlated with transferrin (r -0.73, p<0.05), and HGF levels that resulted positively correlated with BMI (r 0.67, p<0.05). Moving from BHD to HDF, clinical and laboratory parameters were unchanged, as well as serum HGF, whereas myostatin levels significantly decreased (6.3 ± 4.1 versus 4.3 ± 3.1 ng/ml, p<0.05). Conclusions. Modulation of myostatin levels and myostatin/HGF balance by the use of different HD modalities might represent a novel approach to the prevention and treatment of HD-related muscle wasting syndrome.

Original languageEnglish
Article number7635459
JournalBioMed Research International
Volume2017
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Myostatin
Hepatocyte Growth Factor
Renal Dialysis
Modulation
Hemodiafiltration
Bicarbonates
Serum
Wasting Syndrome
Transferrin
Cross-Over Studies
Muscle
Therapeutics
Prospective Studies
Muscles

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities. / Esposito, Pasquale; La Porta, Edoardo; Calatroni, Marta; Grignano, Maria Antonietta; Milanesi, Samantha; Verzola, Daniela; Battaglia, Yuri; Gregorini, Marilena; Libetta, Carmelo; Garibotto, Giacomo; Rampino, Teresa.

In: BioMed Research International, Vol. 2017, 7635459, 01.01.2017.

Research output: Contribution to journalArticle

Esposito, Pasquale ; La Porta, Edoardo ; Calatroni, Marta ; Grignano, Maria Antonietta ; Milanesi, Samantha ; Verzola, Daniela ; Battaglia, Yuri ; Gregorini, Marilena ; Libetta, Carmelo ; Garibotto, Giacomo ; Rampino, Teresa. / Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities. In: BioMed Research International. 2017 ; Vol. 2017.
@article{63c07e8a5052437eb638ab6e0ad8deac,
title = "Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities",
abstract = "Background. In this study we investigated the relevance of myostatin and Hepatocyte Growth Factor (HGF) in patients undergoing hemodialysis HD and the influence of different HD modalities on their levels. Methods. We performed a prospective crossover study in which HD patients were randomized to undergo 3-month treatment periods with bicarbonate hemodialysis (BHD) followed by online hemodiafiltration (HDF). Clinical data, laboratory parameters, and myostatin and HGF serum levels were collected and compared. Results. Ten patients and six controls (C) were evaluated. In any experimental condition myostatin and HGF levels were higher in HD than in C. At enrollment and after BHD there were not significant correlations, whereas at the end of the HDF treatment period myostatin and HGF were inversely correlated (r -0.65, p<0.05), myostatin serum levels inversely correlated with transferrin (r -0.73, p<0.05), and HGF levels that resulted positively correlated with BMI (r 0.67, p<0.05). Moving from BHD to HDF, clinical and laboratory parameters were unchanged, as well as serum HGF, whereas myostatin levels significantly decreased (6.3 ± 4.1 versus 4.3 ± 3.1 ng/ml, p<0.05). Conclusions. Modulation of myostatin levels and myostatin/HGF balance by the use of different HD modalities might represent a novel approach to the prevention and treatment of HD-related muscle wasting syndrome.",
author = "Pasquale Esposito and {La Porta}, Edoardo and Marta Calatroni and Grignano, {Maria Antonietta} and Samantha Milanesi and Daniela Verzola and Yuri Battaglia and Marilena Gregorini and Carmelo Libetta and Giacomo Garibotto and Teresa Rampino",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/7635459",
language = "English",
volume = "2017",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities

AU - Esposito, Pasquale

AU - La Porta, Edoardo

AU - Calatroni, Marta

AU - Grignano, Maria Antonietta

AU - Milanesi, Samantha

AU - Verzola, Daniela

AU - Battaglia, Yuri

AU - Gregorini, Marilena

AU - Libetta, Carmelo

AU - Garibotto, Giacomo

AU - Rampino, Teresa

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background. In this study we investigated the relevance of myostatin and Hepatocyte Growth Factor (HGF) in patients undergoing hemodialysis HD and the influence of different HD modalities on their levels. Methods. We performed a prospective crossover study in which HD patients were randomized to undergo 3-month treatment periods with bicarbonate hemodialysis (BHD) followed by online hemodiafiltration (HDF). Clinical data, laboratory parameters, and myostatin and HGF serum levels were collected and compared. Results. Ten patients and six controls (C) were evaluated. In any experimental condition myostatin and HGF levels were higher in HD than in C. At enrollment and after BHD there were not significant correlations, whereas at the end of the HDF treatment period myostatin and HGF were inversely correlated (r -0.65, p<0.05), myostatin serum levels inversely correlated with transferrin (r -0.73, p<0.05), and HGF levels that resulted positively correlated with BMI (r 0.67, p<0.05). Moving from BHD to HDF, clinical and laboratory parameters were unchanged, as well as serum HGF, whereas myostatin levels significantly decreased (6.3 ± 4.1 versus 4.3 ± 3.1 ng/ml, p<0.05). Conclusions. Modulation of myostatin levels and myostatin/HGF balance by the use of different HD modalities might represent a novel approach to the prevention and treatment of HD-related muscle wasting syndrome.

AB - Background. In this study we investigated the relevance of myostatin and Hepatocyte Growth Factor (HGF) in patients undergoing hemodialysis HD and the influence of different HD modalities on their levels. Methods. We performed a prospective crossover study in which HD patients were randomized to undergo 3-month treatment periods with bicarbonate hemodialysis (BHD) followed by online hemodiafiltration (HDF). Clinical data, laboratory parameters, and myostatin and HGF serum levels were collected and compared. Results. Ten patients and six controls (C) were evaluated. In any experimental condition myostatin and HGF levels were higher in HD than in C. At enrollment and after BHD there were not significant correlations, whereas at the end of the HDF treatment period myostatin and HGF were inversely correlated (r -0.65, p<0.05), myostatin serum levels inversely correlated with transferrin (r -0.73, p<0.05), and HGF levels that resulted positively correlated with BMI (r 0.67, p<0.05). Moving from BHD to HDF, clinical and laboratory parameters were unchanged, as well as serum HGF, whereas myostatin levels significantly decreased (6.3 ± 4.1 versus 4.3 ± 3.1 ng/ml, p<0.05). Conclusions. Modulation of myostatin levels and myostatin/HGF balance by the use of different HD modalities might represent a novel approach to the prevention and treatment of HD-related muscle wasting syndrome.

UR - http://www.scopus.com/inward/record.url?scp=85018661560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018661560&partnerID=8YFLogxK

U2 - 10.1155/2017/7635459

DO - 10.1155/2017/7635459

M3 - Article

AN - SCOPUS:85018661560

VL - 2017

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 7635459

ER -